- Home
- ANTA vs CGTX Comparison
ANTA vs CGTX Comparison
Compare ANTA & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ANTA | CGTX |
|---|---|---|
| Founded | 2022 | 2007 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 96.5M | 79.6M |
| IPO Year | 2024 | 2021 |
Fundamental Metrics
Financial Performance| Metric | ANTA | CGTX |
|---|---|---|
| Price | $3.58 | $1.01 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | ★ $16.17 | $3.33 |
| AVG Volume (30 Days) | 4.5K | ★ 533.1K |
| Earning Date | 06-16-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 62.79 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $21.95 | N/A |
| Revenue Next Year | $30.46 | N/A |
| P/E Ratio | $19.77 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.00 | $0.55 |
| 52 Week High | $13.82 | $3.83 |
Technical Indicators
Market Signals| Indicator | ANTA | CGTX |
|---|---|---|
| Relative Strength Index (RSI) | 39.58 | 48.22 |
| Support Level | $3.00 | $0.91 |
| Resistance Level | $4.17 | $1.18 |
| Average True Range (ATR) | 0.31 | 0.07 |
| MACD | 0.14 | 0.02 |
| Stochastic Oscillator | 49.57 | 48.15 |
Price Performance
Historical ComparisonAbout ANTA Antalpha Platform Holding Company Ordinary Shares
Antalpha Platform Holding Co provides financing, technology and risk management solutions to institutional and corporate customers in the crypto asset industry. The company operates through Antalpha Prime platform in the following areas: Supply chain financing and Technology and services. Its revenue prominently consists of technology financing fees charged on the supply chain loans.
About CGTX Cognition Therapeutics Inc.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system (CNS) and retina. It aims to develop disease-modifying therapies for patients with these disorders. Its product candidate, zervimesine (CT1812), is an orally delivered small molecule designed to protect neuronal synapses by preventing the binding of oligomers of pathogenic proteins, including beta-amyloid and alpha-synuclein. These protein oligomers have been linked to the progression of degenerative diseases such as Alzheimer's disease (AD) and dementia with Lewy bodies (DLB).